ESTRO 2023 - Abstract Book

S684

Monday 15 May 2023

ESTRO 2023

Results Forty patients (median age of 68 years) were accrued in the study. Patient and disease characteristics are summarized in table 1 (A). PTV coverage and dose to the OAR are presented in table 1 (B). OS for the entire cohort is 92.5%; 100% for more prognostically favorable patients treated with VC-SBRT only (group 1) and 80% for those who received also EBRT (group 2). No pelvic or vaginal recurrences were observed in either group. The 3-year actuarial DFS is 82.5% (90% and 67% for group 1 and 2, respectively), with disease progression exclusively occurring distantly, predominantly in the lung. Median survival has not yet been reached. SBRT was well tolerated and no acute/late urinary or gastrointestinal toxicities > grade 2 were observed.

Conclusion Adjuvant vaginal SBRT CV appears to be a safe and effective alternative to BT for stage I-III endometrial cancer. Our preliminary analysis reveals excellent 3-year local control and tolerance. Larger prospective studies and longer follow-up are necessary to establish the role of vaginal SBRT as a new alternative standard of care. PD-0812 Radiation Dose To Bone Marrow Subregions And Acute Hematologic Toxicity In Endometrial Cancer R. Autorino 1 , A. Nardangeli 2 , R. Rinaldi 2 , S. Di Franco 3 , M. Campitelli 3 , V. De Luca 3 , V. Lancellotta 3 , G. Macchia 4 , D. Cusumano 3 , G. Ferrandina 5 , M.A. Gambacorta 3 1 Fondazione Policlinico Universitario "A. Gemelli" IRCCS, UOC Radioterapia Oncologica, Rome, Italy; 2 Fondazione Policlinico Universitario "A. Gemelli, UOC Radioterapia Oncologica, Rome, Italy; 3 Fondazione Policlinico Universitario "A. Gemelli" , UOC Radioterapia Oncologica, Rome, Italy; 4 Molise Hospital, Unità Operativa di Radioterapia, Università Cattolica del Sacro Cuore, Campobasso, Italy; 5 Fondazione Policlinico Universitario A. Gemelli, Woman, Child and Public Health Department, Rome, Italy

Purpose or Objective